A Phase 2 interventional study of Febuxostat and Placebo for Febuxostat in Joint Damage, sponsored by Takeda. Completed at 56 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-10.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing febuxostat in Gout — 1 open to participants now, 1 under way, none of them phase 3. Febuxostat · Gout.
Among the 29 studies testing febuxostat in Gout, this one is the 8th largest by enrollment, is one of 4 that started in 2010, is one of 9 in phase 2, and was the 10th registered.
347 studies on the registry are indexed under Gout; 50 are open to participants now.
Browse Gout studies →1 of the 29 studies testing febuxostat in Gout is open now. Recruiting first, the newest first:
Haiphong University of Medicine and Pharmacy
Healthy volunteers
Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 314 is above the median of 83 across 288 interventional studies indexed under Gout.
Median enrollment 109 across the 29 interventional studies. Of the 27 that completed or were terminated, 18 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 29 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
15 studies in Gout by Takeda: none open now, none under way, none of them phase 3. Of 15 finished, 14 (93%) have results posted.
Among the 15 studies in Gout by Takeda, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2010, is one of 5 in phase 2, and was the 10th registered.
Takeda’s Gout studies by the year they started, since 2001.
1 of the studies testing febuxostat in Gout that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07369622Haiphong University of Medicine and PharmacyHLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness | 2027-06-20 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies testing febuxostat in Gout, from their registry updates:
Among Takeda’s 15 in Gout:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This purpose of this study is to assess the effect of febuxostat, once daily (QD), on joint damage in patients with elevated serum urate levels and gout.
Gout is caused by high levels of uric acid in the body, and is associated with a broad range of comorbidities including heart disease, chronic kidney disease and additional risk factors like obesity and high blood pressure. Hyperuricemia, which is defined as an elevation in serum urate levels, develops into gout when urate crystals form from supersaturated body fluids and settle in joints and other organs. Urate-lowering therapy is used to treat hyperuricemia in patients with gout.
Current treatments focus on initiating urate-lowering therapy in hyperuricemic gout patients who have experienced multiple acute gout flares within the past year. However, joint damage caused by crystal deposition may occur much earlier than previously considered. Monosodium urate crystals have been found present in the joints of people with hyperuricemia who do not have any symptoms. The presence of monosodium urate crystals would indicate that after the crystals form, they stay within the joint if serum urate levels are not reduced. Lowering uric acid levels and maintaining them may reduce acute gout flare episodes and possibly halt or reduce joint damage in patients with gout.
This study will evaluate the effect of febuxostat on joint damage in hyperuricemic patients with early gout. All patients will receive gout flare prophylaxis for the first 6 months of the study. Gout flares may also be treated throughout the study.
A variety of imaging techniques are in use to evaluate gout. Plain radiographs (x-rays), Magnetic Resonance Imaging (MRI) and Dual Energy Computed Tomography (DECT) will be utilized in this study. The modified Sharp/Van Der Heijde scoring method (named after Drs. Sharp and Van Der Heijde) for assessment of x-rays has been validated in patients with chronic gout and will be used in this study for evaluating erosion and joint space narrowing. Participants are expected to have 15 visits which will include plain radiographic examinations at 5 visits, 3 Magnetic Resonance Imaging (MRI) examinations and 3 DECT procedures at selected sites.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must have a history or presence of gout defined as having one or more of the following conditions of the American Rheumatism Association (ARA) preliminary criteria for the diagnosis of gout
History of at least 6 of the following clinical, laboratory and x-ray phenomena*: *More than one flare criteria will be excluded for the purpose of this study if the participant has a history of only a single acute gout flare.
Is male and at least 18 years of age OR;
Exclusion Criteria:
Magnetic Resolution Imaging:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Febuxostat 40 mg or 80 mg (based on serum urate levels at Day 14), capsules, orally, once daily for up to 24 Months.
Drug: Febuxostat
Febuxostat placebo-matching capsules, orally, once daily for up to 24 Months.
Drug: Placebo for Febuxostat
Febuxostat capsules
Also known as: Uloric, TMX-67
Febuxostat placebo-matching capsules
Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint
The single affected joint was defined as the joint with the history of the first acute gout flare. Radiographs (X-rays) of this single joint in the hands or feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst). Individual erosion scores were summed to a maximum erosion score of 5 for joints in the hands and 10 for joints in the feet. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement.
Time frame: Baseline and Month 24
Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Total Scores From Full Hands and Feet Radiographs
Radiographs (X-rays) of 40 joints in the hands and 12 joints in the feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) for a total erosion score range of 0 to 320. Joint space narrowing (JSN) was assessed using a 5-point scale where 0=normal (best) to 4=absence of joint space, presumptive evidence of ankyloses, or complete luxation (worst) for a total JSN score range of 0 to 208. The Erosion Score and the JSN Score were combined for a total possible score of 0 to 528. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement.
Time frame: Baseline and Month 24
Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Scores From Full Hands and Feet Radiographs
Radiographs (X-rays) of 40 joints in the hands and 12 joints in the feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) for a total erosion score range of 0 to 320. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement.
Time frame: Baseline and Month 24
Mean Change From Baseline to Month 24 in the Rheumatoid Arthritis MRI Scoring System (RAMRIS) Score of the Single Affected Joint
The single affected joint was defined as the joint with the history of the first acute gout flare. Magnetic Resonance Imaging (MRI) was evaluated using the Rheumatoid Arthritis MRI Score (RAMRIS). Bone erosion in the proximal and distal location were each assessed in the affected joint using an 11-point scale where 0=no erosion (best) to 10=91-100% bone eroded (worst) for a bone erosion score range of 0 to 20. Bone marrow edema in the proximal and distal location were each assessed using a 4-point scale where 0=no edema (best) to 3=67-100% edema (worst) for a bone marrow edema (BME) score range of 0 to 6. Synovitis was assessed in the affected joint using a 4-point scale where 0=normal (best) to 3=severe (worst). Higher scores indicated more joint damage. A negative change from Baseline indicated improvement.
Time frame: Baseline and Month 24
Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Total Score of the Single Affected Joint
The single affected joint was defined as the joint with the history of the first acute gout flare. Radiographs (X-rays) of the single affected joint in the hands or feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) and Joint space narrowing (JSN) was assessed using a 5-point scale where 0=normal (best) to 4=absence of joint space, presumptive evidence of ankyloses, or complete luxation (worst). The Erosion Score and the JSN Score were summed for the Total Score. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement.
Time frame: Baseline and Month 24
Participants took part in the study at 65 investigative sites in the United States from 10 March 2010 to 3 September 2013.
| Milestone | Febuxostat 40 mg or 80 mg | Placebo |
|---|---|---|
| Started | 157 | 157 |
| Completed | 93 | 90 |
| Not completed | 64 | 67 |
| Withdrew: Adverse event | 10 | 6 |
| Withdrew: Major protocol deviation | 2 | 0 |
| Withdrew: Lost to follow-up | 23 | 23 |
| Withdrew: Voluntary withdrawal | 20 | 36 |
| Withdrew: Other | 9 | 2 |
The single affected joint was defined as the joint with the history of the first acute gout flare. Radiographs (X-rays) of this single joint in the hands or feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst). Individual erosion scores were summed to a maximum erosion score of 5 for joints in the hands and 10 for joints in the feet. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement.
| score on a scale | Febuxostat 40 mg or 80 mg | Placebo |
|---|---|---|
| Baseline | 0.16 ± 0.444 | 0.11 ± 0.438 |
| Change from Baseline at Month 24 | 0.01 ± 0.330 | 0.01 ± 0.248 |
Radiographs (X-rays) of 40 joints in the hands and 12 joints in the feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) for a total erosion score range of 0 to 320. Joint space narrowing (JSN) was assessed using a 5-point scale where 0=normal (best) to 4=absence of joint space, presumptive evidence of ankyloses, or complete luxation (worst) for a total JSN score range of 0 to 208. The Erosion Score and the JSN Score were combined for a total possible score of 0 to 528. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement.
| score on a scale | Febuxostat 40 mg or 80 mg | Placebo |
|---|---|---|
| Baseline | 4.98 ± 9.707 | 4.56 ± 8.631 |
| Change from Baseline at Month 24 (n=78,74) | 0.31 ± 2.447 | 0.29 ± 1.746 |
Radiographs (X-rays) of 40 joints in the hands and 12 joints in the feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) for a total erosion score range of 0 to 320. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement.
| score on a scale | Febuxostat 40 mg or 80 mg | Placebo |
|---|---|---|
| Baseline | 0.36 ± 1.160 | 0.17 ± 0.473 |
| Change from Baseline at Month 24 (n=78,74) | 0.17 ± 1.709 | 0.11 ± 0.969 |
The single affected joint was defined as the joint with the history of the first acute gout flare. Magnetic Resonance Imaging (MRI) was evaluated using the Rheumatoid Arthritis MRI Score (RAMRIS). Bone erosion in the proximal and distal location were each assessed in the affected joint using an 11-point scale where 0=no erosion (best) to 10=91-100% bone eroded (worst) for a bone erosion score range of 0 to 20. Bone marrow edema in the proximal and distal location were each assessed using a 4-point scale where 0=no edema (best) to 3=67-100% edema (worst) for a bone marrow edema (BME) score range of 0 to 6. Synovitis was assessed in the affected joint using a 4-point scale where 0=normal (best) to 3=severe (worst). Higher scores indicated more joint damage. A negative change from Baseline indicated improvement.
| score on a scale | Febuxostat 40 mg or 80 mg | Placebo |
|---|---|---|
| Synovitis:Baseline (BL)(n=82,76) | 1.29 ± 0.782 | 1.09 ± 0.687 |
| Synovitis:Change from Baseline (n=75,67) | -0.43 ± 0.713 | -0.07 ± 0.531 |
| Erosion (Distal+Proximal):Baseline (n=84,77) | 1.63 ± 0.935 | 1.48 ± 0.916 |
| Erosion (Distal+Proximal):Change from BL(n=79,69) | -0.01 ± 0.702 | 0.04 ± 0.475 |
| Edema (Distal+Proximal):Baseline (BL) (n=81,75) | 0.73 ± 1.022 | 0.51 ± 0.919 |
| Edema (Distal+Proximal):Change from BL(n=77,66) | -0.36 ± 0.916 | -0.10 ± 0.962 |
The single affected joint was defined as the joint with the history of the first acute gout flare. Radiographs (X-rays) of the single affected joint in the hands or feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) and Joint space narrowing (JSN) was assessed using a 5-point scale where 0=normal (best) to 4=absence of joint space, presumptive evidence of ankyloses, or complete luxation (worst). The Erosion Score and the JSN Score were summed for the Total Score. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement.
| score on a scale | Febuxostat 40 mg or 80 mg | Placebo |
|---|---|---|
| Baseline | 0.85 ± 1.057 | 0.77 ± 1.022 |
| Change from Baseline at Month 24(n=81,76) | 0.00 ± 0.602 | 0.05 ± 0.361 |
Collected over Treatment-emergent adverse events are adverse events, regardless of relationship to study drug, that started on or after the first dose of study drug and no more than 30 days after last dose of study drug (Up to 25 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Febuxostat 40 mg or 80 mg | — | 13/157 (8.3%) | 73/157 (46.5%) |
| Placebo | — | 11/157 (7%) | 67/157 (42.7%) |
| Event | Febuxostat 40 mg or 80 mg | Placebo |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/157 | 2/157 |
| Cardiac failure congestiveCardiac disorders | 1/157 | 1/157 |
| Acute myocardial infarctionCardiac disorders | 1/157 | 0/157 |
| Angina pectorisCardiac disorders | 1/157 | 0/157 |
| Mitral valve incompetenceCardiac disorders | 0/157 | 1/157 |
| Left ventricular dysfunctionCardiac disorders | 0/157 | 1/157 |
| Atrial fibrillationCardiac disorders | 0/157 | 1/157 |
| Ventricular fibrillationCardiac disorders | 0/157 | 1/157 |
| Vitreous haemorrhageEye disorders | 0/157 | 1/157 |
| Diabetic retinopathyEye disorders | 0/157 | 1/157 |
| Event | Febuxostat 40 mg or 80 mg | Placebo |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 15/157 | 16/157 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 14/157 | 10/157 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 9/157 | 13/157 |
| Aspartate aminotransferase increasedInvestigations | 11/157 | 6/157 |
| Blood creatine phosphokinase increasedInvestigations | 9/157 | 11/157 |
| Alanine aminotransferase increasedInvestigations | 10/157 | 6/157 |
| HeadacheNervous system disorders | 5/157 | 10/157 |
| DiarrhoeaGastrointestinal disorders | 9/157 | 6/157 |
| Gamma-glutamyltransferase increasedInvestigations | 6/157 | 9/157 |
| Back painMusculoskeletal and connective tissue disorders | 9/157 | 6/157 |
| Age, Continuous(years) | Febuxostat 40 mg or 80 mg | Placebo | Total |
|---|---|---|---|
| Mean | 51.4 ± 12.36 | 50.1 ± 11.72 | 50.8 ± 12.04 |
| Age, Customized(participants) | Febuxostat 40 mg or 80 mg | Placebo | Total |
|---|---|---|---|
| <45 years | 49 | 42 | 91 |
| 45 to <65 years | 85 | 99 | 184 |
| ≥65 years | 23 | 16 | 39 |
| Sex: Female, Male(Participants) | Febuxostat 40 mg or 80 mg | Placebo | Total |
|---|---|---|---|
| Female | 14 | 12 | 26 |
| Male | 143 | 145 | 288 |
| Race/Ethnicity, Customized(participants) | Febuxostat 40 mg or 80 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 8 | 10 | 18 |
| Black or African American | 25 | 24 | 49 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| White | 119 | 121 | 240 |
| Other | 3 | 2 | 5 |
| Race/Ethnicity, Customized(participants) | Febuxostat 40 mg or 80 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 26 | 36 | 62 |
| Not Hispanic or Latino | 131 | 121 | 252 |
| Region of Enrollment(participants) | Febuxostat 40 mg or 80 mg | Placebo | Total |
|---|---|---|---|
| United States | 157 | 157 | 314 |
| Height(cm) | Febuxostat 40 mg or 80 mg | Placebo | Total |
|---|---|---|---|
| Mean | 176.3 ± 9.22 | 176.5 ± 8.36 | 176.4 ± 8.79 |
| Weight(kg) | Febuxostat 40 mg or 80 mg | Placebo | Total |
|---|---|---|---|
| Mean | 102.8 ± 20.88 | 100.7 ± 21.20 | 101.7 ± 21.04 |
5 further baseline measures are reported on the registry.
The record gives a start of Mar 2010, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Febuxostat